tradingkey.logo

Cancer therapy firm Erasca drops after $150 mln stock offering unveil

ReutersJan 20, 2026 9:46 PM

Erasca ERAS.O shares down 8.1% in extended trading to $9.02 after equity raise news

San Diego, California-based oncology co announces $150 mln stock offering

Co intends to use net offering proceeds to help fund R&D of its product candidates and other development programs, and for working capital and other general corporate purposes

JP Morgan, Morgan Stanley, Jefferies and Evercore joint bookrunners

With ~283.7 mln shares outstanding, co has about $2.8 bln market cap

ERAS shares on Tues finished session up 2% at $9.81, up 164% to begin 2026

Of 11 analysts covering the stock, recommendation breakdown is 9 "strong buy" or "buy", 1 "hold" and 1 "sell"; median PT $7.50, LSEG data reflects

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI